Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL)
- 23 September 2001
- journal article
- clinical trial
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 40 (1) , 37-51
- https://doi.org/10.1016/s1040-8428(01)00133-0
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Pretargeted Radioimmunotherapy (PRIT™) for Treatment of Non-Hodgkin's Lymphoma (NHL): Initial Phase I/II Study ResultsCancer Biotherapy & Radiopharmaceuticals, 2000
- Radiation Absorbed Dose Estimation for 90Y-DOTA-biotin with Pretargeted NR-LU-10/StreptavidinCancer Biotherapy & Radiopharmaceuticals, 1999
- Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's LymphomasJournal of Clinical Oncology, 1999
- Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1998
- Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.Journal of Clinical Oncology, 1996
- Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomasThe Lancet, 1995
- Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow SupportNew England Journal of Medicine, 1993
- Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) AntibodyNew England Journal of Medicine, 1993